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Abstract
Dendritic cells (DCs) generated in vitro to present tumour antigens have been injected in cancer patients to boost in vivo
anti-tumour immune responses. This approach to cancer immunotherapy has had limited success. For anti-tumour therapy,
delivery and subsequent migration of DCs to lymph nodes leading to effective stimulation of effector T cells is thought to
be essential. The ability to non-invasively monitor the fate of adoptively transferred DCs in vivo using magnetic resonance
imaging (MRI) is an important clinical tool to correlate their in vivo behavior with response to treatment. Previous reports of
superparamagnetic iron oxides (SPIOs) labelling of different cell types, including DCs, have indicated varying detrimental
effects on cell viability, migration, differentiation and immune function. Here we describe an optimised labelling procedure
using a short incubation time and low concentration of clinically used SPIO Endorem to successfully track murine DC
migration in vivo using MRI in a mouse tumour model. First, intracellular labelling of bone marrow derived DCs was
monitored in vitro using electron microscopy and MRI relaxometry. Second, the in vitro characterisation of SPIO labelled DCs
demonstrated that viability, phenotype and functions were comparable to unlabelled DCs. Third, ex vivo SPIO labelled DCs,
when injected subcutaneously, allowed for the longitudinal monitoring by MR imaging of their migration in vivo. Fourth, the
SPIO DCs induced the proliferation of adoptively transferred CD4
+ T cells but, most importantly, they primed cytotoxic CD8
+
T cell responses to protect against a B16-Ova tumour challenge. Finally, using anatomical information from the MR images,
the immigration of DCs was confirmed by the increase in lymph node size post-DC injection. These results demonstrate that
the SPIO labelling protocol developed in this study is not detrimental for DC function in vitro and in vivo has potential
clinical application in monitoring therapeutic DCs in patients with cancer.
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Introduction
The ability to non-invasively image adoptively transferred
dendritic cell (DCs) in vivo during cellular immunotherapy could
be used to assess the in vivo behavior of injected DCs and correlate
it to the clinical response to therapy. In particular, the ability to
quantify the number of injected DCs that have migrated from the
injection site to the draining lymph nodes (LN) would be a
valuable clinical tool. To date, however, there has been limited
success of DC based immunotherapies and many questions remain
with regard to appropriate sites of delivery, frequency of delivery,
cell number, DC phenotype, and optimal antigen for the most
robust immune stimulation or tolerance induction [1]. Molecular
imaging may provide some of the answers to these questions by
using superparamagnetic iron oxide (SPIO) labelled DCs (SPIO
DCs). To date, studies of SPIO DCs in vivo have focused mostly on
evaluating their migratory properties using MRI and evaluating
cell surface markers that are required for afferent LN migration
but not on SPIO DC in vivo function [2,3,4,5,6].
Initial proof of concept studies demonstrated that DCs could be
labelled with SPIOs and then monitored in vivo over time by MRI
[2]. The efficiency of SPIO labelling of DCs was further enhanced
by using SPIOs conjugated to anti-CD11c antibodies, resulting in
a 50-fold increase in SPIO labelling of DCs [2]. However, this
intense loading with SPIOs, with 30 pg or higher of iron per cell,
was shown to adversely affect DC viability and migration by
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labelled DCs has also led to the discovery that the receptors CCR7
[4] and RAGE [5] are required for DC migration. Furthermore,
MRI has allowed the study of DC migration to draining LNs in a
semi-quantitative manner, showing a correlation between hypoin-
tensity in draining LNs and number of DCs injected [6]. In a
recent study, rapamycin treated tolerogenic DCs were used in a
graft-vs-host disease (GVHD) model where recipient tolerogenic
DCs prolonged survival and decreased GVHD score on day seven
post-bone marrow transplantation [7]. Monitoring of DC
migration in this GVHD model, using tolerogenic DCs labelled
with SPIO, showed hypointensity via MRI in the cervical LN eight
days after injection, demonstrating the application of this
approach to in vivo study of DC function. However, this study
did not perform a comparison of SPIO labelled and unlabelled
DCs. Similarly the cell numbers that migrated to LNs after
injection were not quantified using SPIO labelled DCs [7]. Finally,
in a clinical study the use of MRI and SPIO labelled human DCs
has demonstrated that only around 50% of the cases the DCs were
correctly injected into the lymph node despite ultrasound guidance
and showed subsequent migration to other local LNs, [8].
Altogether, investigations to date have not studied the effect of
SPIO labelling on DC immunological function in vivo compared
to their unlabelled counterparts. So far SPIO labelled and
unlabelled DCs have been compared for their ability to initiate T
cell proliferation in vitro. Baumjohann et al. demonstrated that the
capacity of SPIO DCs to prime an antigen-specific syngeneic T
cell response by in vitro re-challenge was reduced by ,30%
compared to unlabelled DCs [4]. The authors suggested that the
antigen presentation capacity of SPIO DCs remained intact in
vivo but that SPIO-loading may have minor influences on
migration and uptake or processing of antigens [4]. In a more
recent paper using a low SPIO labelling efficiency of ,6 pg iron
per cell, a 15% decrease in ex vivo T cell proliferation was
demonstrated when compared to unlabelled DCs [6]. The
decreased stimulatory capacity of SPIO DCs compared to
unlabelled DCs was confirmed further by demonstrating a
decrease in their endocytic function by using dextran-FITC or
fluorescently labelled apoptotic cells [6]. The explanation offered
by the authors was that the dextran coat on SPIOs may impede
the uptake of other glycosylated antigens through endocytosis.
Utilising GFP
+ DCs, they also showed that the number of GFP
+
cells in the draining LN was reduced when DCs were SPIO
labelled. The same group has repeated this using micrometer-
sized iron oxides (MPIOs) and reported similar results where
MIPO labelling decreased DC migration in vivo [9].
In this study, SPIO DC labelling efficiency, intracellular SPIO
distribution, viability, phenotype, and ability to induce T cell
proliferation were assessed in vitro and compared to unlabelled
DCs. MRI was applied to monitor SPIO DC migration in vivo to
the popliteal LN. When monitoring the migration of DCs over
time, both SPIO labelled or unlabelled caused a similar increase in
popliteal LN volume. DCs were labelled with sufficient SPIO to
induce contrast hypointensity via MR imaging without affecting
their in vivo function as compared to unlabelled DCs. This was
demonstrated by an in vivo proliferation assay and the ability of
SPIO DCs to induce protection against an Ova-B16 melanoma
tumour challenge.
Materials and Methods
Ethics statement
Animal studies were carried out in accordance with UK
Research Councils’ and Medical Research Charities’ guidelines on
Responsibility in the Use of Animals in Bioscience Research,
under a UK Home Office license (PPL# 70/6473; Title:
Mechanisms of immunological response to foreign antigens).
Mice, culture media, reagents and antibodies
C57BL/6 (H2
b) and CBA/Ca (H2
k) mice were ordered from
Harlan Olac (Bicester, UK). OT-II and DO11.10 were bred and
maintained in the Biological Services Unit at King’s College
London. RPMI 1640 medium (Sigma, Poole, UK) supplemented
with 5 mM L-Glut (Invitrogen, Paisley, UK), 100 U/mL penicillin
(Invitrogen), 100 mg/mL streptomycin (Invitrogen), 10% FCS
(Harlan Sera-Lab, Loughborough, UK), 1 mM Hepes (Invitrogen)
and 0.05 mM mercaptoethanol (Invitrogen) is used for all in vitro
assays. DC media also contains 5% (vol/vol) supernatant from a
granulocyte macrophage colony-stimulating factor (GM-CSF)
secreting transfected cell line [10]. For T cell purification and
washing steps, RPMI 1640 medium supplemented with 2% fetal
calf serum (FCS) was used. Flow Cytometry was performed using a
FACSCalibur (BD Biosciences) and the following phycoerythrin
(PE)-conjugated antibodies (Abs): MHC-class I (IK
b), MHC-class
II (IA
b), CD80, CD86, CD40, CD11c, CD54 and CCR7, and
allophycocyanin conjugated anti-CD4. All antibodies and isotype
controls were used according to manufacturer’s instructions (BD
Biosciences).
Generation and SPIO labelling of mature bone marrow
derived dendritic cells
DCs where generated as previously described [10,11]. Briefly,
bone marrow was isolated and treated with red blood cell (RBC)
lysis Ack Buffer (150 mM NH4Cl, 1 mM KHCO3, 0.1 mM Na2-
EDTA). Cells were then treated with a mixture of rat anti-mouse
hybridoma supernatants containing anti-H2-E
k,d/A
b,d (M5/
114.15.2, TIB-120; ATCC, Manassas, USA), anti-CD45R/B220
(RA3-3AI/6.1; ATCC), anti-CD4 (YTS191; Therapeutic Immu-
nology Group, Oxford, UK) and anti-CD8 (YTS169; Therapeutic
Immunology Group). After washing with PBS, cells were
incubated with goat anti-rat IgG DynaBeads (Dynal,Oslo, Nor-
way) before separation in a magnetic field for negative isolation.
Cells are resuspended in complete media plus GM-CSF and plated
on 24-well plates (Barloworld Scientific, Staffordshire, UK) in
1 mL fractions at 1 –1.5610
6 cells/mL. Complete media plus
GM-CSF was changed on days 2 and 4, removing non-adherent
cells. On Day 7 DCs were harvested, incubated with 1 mg/mL of
LPS (Sigma, E. Coli 026:B6) for 4 h, re-plated at 1610
6 cells/mL
in a 24-well plate and concurrently incubated with or without
100 mg/mL of SPIO. Cells were washed three times with PBS
before use in subsequent assays. The clinically approved SPIO
agent Endorem was purchased from Gubert, France.
Iron Quantification of SPIO labelled DCs
The average iron quantity per cell was calculated using the
previously described calorimetric ferrozine-based assay [12].
Briefly, 2610
6 cells were counted, pelleted and lysed at 280uC
for 30 min. and then shaken at room temp for 2 h in 200 mLo f
50 mM NaOH. 100 mL of lysate was added to 100 mLo f1 0m M
HCl and 100 mL of iron releasing agent (freshly mixed solution of
equal volumes of 1.4 M HCl and 4.5% (w/v) KMnO4 (Merck) in
dH2O) for 2 h at 60uC. Once cool, 30 mL of iron detection reagent
was added (6.5 mM FerroZine, 6.5 mM Neocuproine, 2.5 M
ammonium acetate, 1 M ascorbic acid) for 30 min. 280 mL was
transferred to a 96-well plate and absorbance is read at 550 nm.
All samples were run in triplicate and compared to known
concentrations of ferric chloride.
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SPIO labelled and unlabelled DCs were fixed for 1 h in 2%
gluteraldehyde in 0.1 M phosphate buffer (pH 7.2) and post-fixed
in 1% aqueous osmium tetroxide. Samples were then dehydrated
through a graded series of ethanol and embedded in TAAB resin.
Sections 70 nm thick were cut using a Leica ultracut E ultra
microtome (Leica, Milton Keynes, UK), mounted on 200 mesh Cu
grids (Agar Scientific, Stanstead, UK), and stained with 1.5%
uranyl acetetate in 50% ethanol and 0.15% lead citrate before
viewing on a Tecnai T12 electron microscope (FEI, the Nether-
lands). Images were captured using a Gatan Bioscan 792 camera
(Gatan, Abington Oxon, UK). Energy filtered transmission
electron microscopy (EFTEM) is a transmission electron micros-
copy technique in which those electrons that have suffered specific
energy loss due to interaction with the atomic nuclei of a given
element are used to form an image of the distribution of that
element. EFTEM was carried out using a G2 Sphera 200 kV
electron microscope (FEI, the Netherlands) fitted with a LaB6
emitter. Sections were imaged in transmission mode. Maps of Fe
distribution were obtained with a GIF 2002 imaging filter, using
TIA software.
Magnetic Resonance Imaging
For the in vitro study MR relaxometry measurements were
performed on a 1.5 T clinical whole-body MR unit (Achieva;
Philips Medical Systems, UK). In order to study the influence of
the labelled cells on the MRI contrast, different concentrations of
SPIO labelled cells were imaged by multi-gradient-echo MR-
sequence. For this, SPIO labelled DCs were diluted in 2-fold
dilutions from 1610
6 to 6.25610
5 cells/mL gelatin (Sigma) and
aliquoted in glass tubes that were then added to a gelatin filled
dish. Also, free SPIO in gelatin was diluted in 2-fold dilutions from
50 to 0.78 mg SPIO per mL.
For quantification of the labelling process R2’ parameter maps
were used to differentiate cell-bound SPIO from free SPIO were
calculated using the relationship: R2’=R 2
* -R 2 [13]. For this,
relaxation R2 and R2
* rates were measured using a multi- spin-
echo and gradient-echo sequences respectively to give magnitude
based images at increasing echo-times (TEs). Taking the data on a
pixel-by-pixel basis and plotting against its TE, a mono-
exponential decay function of the form Mo.exp(-R2
(*).TE) was fit
to give maps of the respective relaxation rates. The R2 map was
thus subtracted from the map for the R2
* relaxation rate taken at a
similar geometric position, to generate a map for R2’.
MRI for the in vivo imaging of DC migration to the lymph node
was performed on a clinical whole-body 3 T scanner (Philips
Achieva) utilizing a 47 mm Philips microscopy coil. Mice were
imaged sequentially by MRI on Days 0, 1, 2, and 4. MRI data was
acquired using a gradient echo sequence with: flip angle =25u;
FOV =4563068 mm; matrix =2966292; slice thickness =0.5 mm;
TE/TR =4.6 ms/15 ms. As methods for detection of SPIO
labelled DCs gradient echo images at longer echo times were
used. Furthermore, a positive contrast technique with suscepti-
bility gradient mapping using original resolution (SUMO) allows
the selective visualization by post-processing [14]. The technique
also provides quantitative information by measurement of the
susceptibility gradient, Gs, from the SUMO parameter maps
used for positive contrast.
Flow cytometry analysis
All flow cytometry acquisition and analysis was performed on a
Becton Dickinson FACSCalibur running CellQuest software
(Becton Dickinson, Oxford, UK) and FlowJo (Oregon, USA).
For phenotype surface staining, 5610
5 DCs were incubated
according to manufacturer’s instructions with various antibodies in
FACS Buffer (PBS plus 1% (vol/vol) FCS and 0.01% (w/vol)
sodium azide) for 30 min. at 4uC in the dark followed by two
washes in FACS Buffer. For in vivo proliferation experiments, flow
cytometry is described in the methodology of the assay.
Dendritic cell viability assays
Viability assays were performed at 4 or 18 h of SPIO labelling
at 50, 100, or 150 mg SPIO per mL culture media. DCs incubated
with SPIO under various labelling conditions were harvested and
counted after the labelling procedure in a haemocytometer in the
presence of Trypan Blue (Sigma). For the MTT assay, DCs
incubated with SPIO under various labelling conditions were
harvested and re-plated in a flat-bottomed 96-well plate (Iwaki) at
1610
5 cells per 100 mL media in triplicate. 10 mL of 5 mg/mL 3-
[4,5-dimethylthiasol- 2-yl]-2,5-diphenyltetrazolium bromide (MTT,
Sigma) was added to each well and incubated at 37uCf o r4h .
100 mL of 10% SDS in 1 mM HCl was added to each well and
incubated at 37uC overnight. The absorbance of each well was read
in a BioTek spectrophotometer at 570 nm.
CD4
+ T cell isolation
Spleens and lymph nodes (LN) were homogenized over 70 mm
cell strainers (Beckman Coulter) to obtain a single cell suspension
that was treated with ACK buffer. The washed cells were then
incubated with a mixture of rat anti-mouse hybridoma superna-
tants containing anti-H2-E
k,d/A
b,d, anti-CD45R/B220, and anti-
CD8 followed by goat anti-rat IgG DynaBeads before separation
in a magnetic field. Purity of negatively selected CD4
+ population
was .93% before immediate use in further assays.
In vitro proliferation assays
All proliferation assays were done in triplicate in 96-well plates
with a volume of 250 mL. For peptide pulse OT-II proliferation
assays, C57BL/6 DCs that had been treated 6 SPIO and with
LPS were pulsed with Ova3222332 that binds MHC-class II (A
b)a t
0.1 mg/mL for 30 min. After peptide pulse, the DCs were
irradiated (,3000 rad) and plated at 5610
4 DCs/well. DCs were
incubated with freshly isolated CD4
+ T cells from OT-2 transgenic
mice from the spleen and lymph nodes and were mixed at various
DC:T cell concentrations. Proliferation was assessed by
3H-
thymidine incorporation in the last 18 h of 4-day cultures. Mixed
lymphocyte reactions (MLRs) were performed similarly with
irradiated DCs incubated with freshly isolated CBA/Ca CD4
+ T
cells at various DC:T cell concentrations. Again, proliferation was
assessed by
3H-thymidine incorporation in the last 18 h of 4-day
cultures. For protein pulse assays, DCs were treated with 10 mg/
mL Ova protein (Sigma) for 4 h before SPIO labelling. After
irradiation, DCs were incubated with isolated CD4
+ T cells from
OT-II mice at various DC:T cell concentrations. Proliferation was
assessed by
3H-thymidine incorporation in the last 18 h of 4-day
cultures.
In vivo proliferation assay
Freshly isolated OT-II CD4
+ T cells were incubated with
1 mM CFSE in 10 mL PBS per 1610
7 cells for 5 min. at 37uC
and checked by flow cytometry for effective staining. 4610
6 cells
in PBS were i.v. injected on Day 6. On Day 7 of DC culture,
1610
6 mature Ova3222332 pulsed DCs labelled with or without
SPIO were injected in PBS s.c. in the heel. Animals were culled
on Day 11 and specified organs were harvested. 1.5610
6 cells
isolated were stained with anti-CD4-APC and 1610
6 events were
collected for analysis by flow cytometry. Percent original dividing
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divided assuming that no cells died during the experiments. It
was calculated by: (the total number of parent cell that had
divided)/(the calculated number of total parent cells)x100. The
proliferation index (PI) was the average number of divisions that
the dividing cells have undergone. It was calculated by dividing
the total number of events by the calculated number of parent
cells.
Tumour vaccination
On Day 0, C57BL/6 mice were s.c. immunised with 1610
6
DCs pulsed with Ova2572264 (SIINFEKL), labelled with and
without SPIOs. On Day 4, 1610
6 B16 melanoma tumour cells
expressing Ovalbumin and GFP were i.v. injected. Lungs were
then harvested on Day 18 and counted for tumour nodules until a
limit of 250 nodules per lung.
Histology
Live DCs were allowed to bind to glass coverslips (Hendley,
Essex, UK), fixed with 4% paraformaldehyde (PFA) for 10 min.
on ice, washed two times with PBS and one time with dH2O.
Slides were then added to 2% (w/vol) potassium ferrocyanide
(Sigma) in 1 M HCl for 20 min. at RT. After two washes in PBS,
slides are counterstained for 5 min. with Nuclear Fast Red (1%
(w/vol) NFRed with 5% aluminum sulfate; Sigma) and washed
again with PBS then dH2O. Mounting solution (Dako) was
added before the addition of coverslip and imaging using a Lecia
Leitz DMRB research microscope and Micro-Publisher 3.3
RTV camera. Freshly isolated LNs were embedded in OCT and
snap-frozen in liquid nitrogen and stored at -80uCu n t i l
sectioning. Prussian blue staining was performed with 17 mm
sections that were fixed in ice-cold acetone for 1 min. Sections
were then mixed for 30 min. at 37uCi n2 %( w / v )p o t a s s i u m
ferrocyanide (Sigma) in 0.5 M HCl. After thorough washing in
water, sections were counter stained in 0.1% (w/v) Nuclear Fast
Red (Sigma) with 5% aluminum sulfate. Slides were then
mounted with Dako fluorescent mounting media for immediate
imaging using a Lecia Leitz DMRB research microscope and
Micro-Publisher 3.3 RTV camera. Images were analyzed with
Image-Pro Plus 7.0 from Media Cybernetics software and
Photoshop.
Statistics
A t-test was performed to determine if there was a significant
difference in percentage growth of LNs, in vivo proliferation or
gradient susceptibility between SPIO labelled DCs and unlabelled
DC; P-values of ,0.05 were considered significant. To test for a
significant differences between the Control, SPIO DC, DC +
OVA peptide and SPIO DC + OVA peptide in the tumour
challenge experiment, a One-Way ANOVA was first performed;
P-values of ,0.05 were considered significant. If the One-Way
ANOVA was significant, then a post hoc analysis was performed
with Student–Newman–Keuls pairwise comparison; P-values of
,0.05 were considered significant.
Results
DCs can be efficiently labelled with SPIOs while
maintaining their viability
In order to identify the optimal conditions for SPIO labelling of
DCs using the clinically approved SPIO Endorem, various iron
concentrations (50, 100, and 150 mg/mL) and incubation times (4
to 18 h) were investigated. No adverse effects were observed for all
labelling conditions using both trypan blue and MTT assays. Due
to previous literature reports of decreased viability, phagocytic
function, and mobility at higher concentrations of SPIO and
longer incubation times, SPIO labelling was performed at 100 mg/
mL of Endorem for 4 h at 37uC [3,6].
The average concentration of iron per cell under this labelling
condition was determined by the ferrozine-based spectrophoto-
metric iron quantification assay and showed an average of 7 pg
iron per cell. The amount of iron in the cells was evaluated by
using the Prussian blue stain (Figure S1). As reported before, the
SPIO labelling was heterogeneous and some cells were heavily
labelled while some not at all [4]. However, prussian blue staining
revealed that .90% of DCs were stained blue for iron after SPIO
labelling as seen by the presence of any blue stain in the DC under
high magnification. Standard transmission electron microscopy
(TEM) was performed to further analyse intracellular iron.
Unlabelled cells did not show dark endosomal-like compartments
as seen with SPIO labelled DCs (Figure 1A–C). To confirm that
these dark regions within the DCs were SPIOs, energy filtered
transmission electron microscopy (EFTEM) was used to map the
iron and oxygen distribution within SPIO labelled DCs. Both the
EFTEM analysis for oxygen and iron showed similar cellular
localisation results (Figure 1D and E).
To ensure that the SPIO labelling condition changed the
contrast in an MR image, SPIO DCs were set in gelatin at
decreasing concentrations, imaged in a 1.5 T MRI scanner and
compared to control unlabelled DCs (Figure 1F). At a TE of
22.5 ms, SPIO labelled DCs at 2.5610
5 cells/mL were more
hypointense compared to control unlabelled DCs. Utilising R2,
R2
* and R2’ maps, intracellular iron uptake was confirmed in a
phantom experiment (Figure S2A–C) [13]. The difference
between R2 and R2
* mapping was used to determine R2’, which
increases in the presence of intracellular iron. The R2 and R2
*
maps were used to show an increase in R2’ values from SPIO DCs
as compared to free SPIO in gelatin (Figure S2D).
SPIO labelling did not affect the phenotype and in vitro
function of DCs
The phenotype of SPIO DCs after maturation with LPS was
analyzed by flow cytometry and compared to unlabelled DCs.
Analysis of the common DC surface markers such as MHC-class I,
MHC-class II, CD11c, CD40, CD80, CD86, CD54 and CCR7
showed that the phenotype of DCs with and without SPIO
labelling was very similar (Figure S3).
The functionality of SPIO DCs was analyzed firstly by assessing
their T cell stimulatory capacity in vitro. SPIO labelled and
unlabelled, LPS treated DC derived from BL/6 mice were pulsed
with Ova3222332 peptide and then incubated with freshly isolated
CD4
+ T cells from OT-II mice (transgenic mice with a TCR
specific for Ova, peptide 322–332, and restricted by H-2A
b)a t
different DC:T cell ratios (Figure 2A). SPIO labelling of DCs did
not influence OT-II CD4
+ T cell proliferation. To test for the
ability of SPIO DCs to retain efficient antigen processing and
presentation functions, DCs were pulsed with the whole Ova
protein for 4 h, prior to LPS maturation and SPIO labelling. DCs
were then incubated with freshly isolated OT-II CD4
+ T cells
(Figure 2B). As presented in Figure 2B there was no change in the
ability of SPIO DCs to stimulate antigen-specific CD4
+ T cells.
The functional consequence of SPIO labelling of DCs was also
tested in MLR (Figure 2C). DCs derived from BL/6 mice were
incubated with freshly isolated CD4
+ T cells from CBA/Ca mice
at different DC:T cell ratios. As shown in Figure 2C, SPIO
labelling did not influence the stimulatory ability of DCs in a
MLR.
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To determine the effect of SPIO labelling on DC migration in
vivo, mice were injected with 1610
6 SPIO DCs in the right leg and
1610
6 unlabelled DCs in the left leg. Mice were then imaged at 4,
24, 48, and 96 h post-DC injection (Figure 3A). This longitudinal
imaging showed hypointensity as early as 24 h post-injection in the
right popliteal LN as well as the original injection site. The
hypointensity increased from 24 to 48 h post-DC injection. At
96 h, the hypointensity of iron in the right popliteal LN decreased.
Furthermore, there was no significant difference in percentage LN
increase between the right (SPIO labelled) and left popliteal LNs
(unlabelled) (P=0.1888). This indicated that the LNs grew
similarly in size over time as a result of immune activation
(Figure 3B). Indicating that in vivo there is no difference in
migration and immune activation between unlabelled and SPIO
labelled DCs.
Gradient echo MRI with longer echo times TE were used for
visualization of iron in the popliteal LNs due to SPIO DC
migration. MR Images of mice at 48 h post-DC injection with
echo times of 4.6, 9.2, and 13.8 ms are shown in Figure S4A, B
and C, respectively. The left popliteal LN, where unlabelled DCs
were injected, showed no noticeable decrease in signal intensity
with increase in TE. In fact, the LNs retain the ‘‘white’’ contrast
while most of the signal was lost in the surrounding tissue. In the
right LN, however, SPIO DCs caused a clear hypointensity
present at 4.6 ms and increased at longer TEs.
As a second method for the detection of SPIO-labelled DCs the
SUMO-technique was used for visualization with positive contrast
(Figure 4). In both LNs there was positive contrast around the LNs
Figure 1. SPIO labelling of murine bone marrow derived DCs. Standard electron micrographs of A) unlabelled DCs, B) DCs incubated with
100 mg/mL of SPIO for 4 h at 37uC and C) enlarged region within a SPIO DC highlighting dark areas that contain iron oxide. Energy filtered
transmission electron microscopy (EFTEM) of D) iron and E) oxygen. F) SPIO labelled cells were mixed in gelatin phantom at decreasing
concentrations and imaged in a 1.5 T MRI with a T2* acquisition and a TE of 22.5 ms.
doi:10.1371/journal.pone.0019662.g001
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that have SPIO DCs injected, there was a region of positive
contrast in the centre of the LN (Figure 4B) whereas unlabelled
DCs caused minimal positive contrast in the centre of the LN
(Figure 4C). Furthermore, quantitative information over the
longitudinal study was obtained by measurement of the suscep-
tibility gradient, Gs, from the SUMO parameter maps (Figure 4D)
and Gs was significantly higher for SPIO labelled DCs than
unlabelled DC (P,0.038).
From the periphery, DCs enter afferent lymphatic vessels to
migrate to and enter the LNs. Upon entrance to the LN they
reside in the subcapsular sinus before migrating to the cortex of the
LN where they present antigen to lymphocytes. To confirm the
presence of iron in popliteal LNs after SPIO labelled DC were
injected, as shown in the MRI images; prussian blue staining with
a nuclear fast red counter-stain was performed on tissue cryo-
sections (Figure S5). Popliteal LN samples taken 48 h post SPIO
labelled DC injection reveals iron in both the subcapsular sinus
and in the centre of the popliteal LN.
SPIO DCs induced in vivo T cell proliferation and
protected against tumour challenge
If SPIO DCs are to be used to monitor adoptively transferred
DCs in the clinic, then it is important to establish whether SPIO
DCs can migrate and stimulate T cell proliferation in vivo in an
equivalent manner to unlabelled DCs. To test this, mice initially
received naı ¨ve CFSE
+ OT-II CD4
+ T cells followed 24 hours later
by DC injection. Popliteal and mesenteric LNs were collected for
individual analysis by flow cytometry 4 days after DC injections
(Figure 5). When mature, Ova3222332 pulsed DCs were injected
subcutaneously, proliferation was observed in the popliteal LN as
seen by CFSE dilution of CFSE
+ OT-II CD4
+ T cells (Figure 5A).
As expected, in the mesenteric LN little proliferation was observed
(Figure 5B). Flow cytometry histograms of cells from three mice
showed T cell proliferation in popliteal LNs when DCs were
Ova3222332 pulsed and not mesenteric LNs (Figure 5C). As a
control, no proliferation was seen when injected DCs were not
pulsed with Ova3222332 peptide. The percentage of original
CFSE
+ OT-II CD4
+ T cells dividing in the popliteal LN was 42.5
6 1.3% and 40.1 6 1.1% in unlabelled and labelled DC,
respectively, while in the control mesenteric LN it was 9.9 6 0.3%
(data not shown). Similarly, the proliferation index (PI) of
unlabelled and SPIO labelled DCs was 2.5 6 0.04 and 2.3 6
0.1, respectively, whereas the control mesenteric LN gave rise to a
PI of 1.2 6 2.1610
28 (Figure 5D). Therefore, there was no
significant difference between SPIO labelled and unlabelled DCs
(P,0.061) in the ability to initiate T cell proliferation in the
popliteal LN.
To further investigate whether SPIO labelling can affect DC
function in vivo a tumour model was used. Mice were vaccinated in
both heels with 1610
6 mature Ova2572264 pulsed DCs that were
either SPIO labelled or unlabelled. Four days later, mice were
challenged i.v. with 1.5610
6 B16-Ova melanoma cells. Fourteen
days later, mice were sacrificed and surface lung nodules were
counted (Figure 6). Mature, Ova2572264 pulsed, SPIO labelled and
unlabelled DCs reduced the average number of tumour nodules to
1.061.4 and 3.261.9, respectively, per lung as compared to
control mice with no therapy that had .250 nodules per lung
(Figure 6). A statistical significant difference in distribution of
tumour nodule counts was found between all four groups
(p,0.0001). Importantly, no significant difference in the efficacy
of tumour vaccination was detected between SPIO DCs +
Ova2572264 (labelled) and DCs + Ova2572264 (unlabelled)
(P.0.05) and both were significantly different from control or
SPIO DC (P,0.001).
Discussion
In this manuscript we have shown that SPIO labelling of DCs,
using the conditions selected in this study, (i) does not affect the
viability and phenotype of DCs; (ii) does not affect their
stimulatory capacity in vitro and in vivo; (iii) allows the visualization
of SPIO DC migration to the popliteal LNs over time and (iv)
allows the visualization of DC contribution to anti-tumour
responses. Altogether these results support the use of MRI to
follow DCs injected in vivo for either the induction of an anti-
tumour response or for their capacity, when ‘‘tolerogenic,’’ to
prevent allograft rejection or autoimmune diseases.
Recent reports in the stem cell field, comparing SPIO labelling
and reporter gene imaging of transplanted stem cells in the
myocardium, have shown that while hypointensity due to SPIO is
retained in the heart for up to 40 days, reporter gene imaging of
the same cells is gone after 3 days [15,16,17]. SPIO was found to
be localized in macrophages while no stem cells were present in
histological analysis. These results show that while MRI can be
used to track cells, the presence of SPIO can lead to false results
due to their retention in tissue by other cell types. However, here
we use mature DCs that show active migration from the periphery
to the popliteal LN. Moreover, the life span of an activated or
mature dendritic cell in vivo, while somewhat varying according to
type and origin, is only a few days and therefore the use of SPIO to
MR image DCs over a few days seems appropriate. Furthermore,
we predicted that if the signal reduction resulted from free SPIO
engulfed by host macrophages or DCs, this signal would have only
been observed at the subcapsular region of the LN and not in both
the subcapsular sinus and the centre of the popliteal LN as we
observed [4,18].
SPIO labelling of cells together with MRI can offer many
advantages. As shown here MRI can reveal that the migration of
mature, activated DCs to a LN caused LN growth or swelling.
Furthermore, the strongest SPIO effect of hypointensity occurred
24–48 h after DC injection and was similar to previously reported
results [4]. A recent publication has suggested that vaccination
using SPIO labelled dying tumour cells allowed the imaging of
endogenous DCs trafficking following the engulfment of the SPIO
labelled tumour cells [18]. The signal in the popliteal LN was first
detected day three post-tumour injection and reached a maximum
at day 8 [18]. Therefore, in this study, the hypointensity in the
popliteal LN was due to the migration of the injected cells and not
host DCs that engulf the SPIO labelled DCs and subsequently
migrate. In a more recent study, MPIO labelled DCs caused an
Figure 2. In vitro proliferation assays. A) SPIO labelled and unlabelled DCs (4 h at 100 mg/mL SPIO) were LPS treated and pulsed with Ova322-332
peptide for 30 min. Cells were then incubated with 5610
5 CD4
+ T cells at varying DC dilutions. B) SPIO labelled and unlabelled DCs (4 h at 100 mg/mL
SPIO) were LPS treated and pulsed with whole Ova protein for 30 min. Cells were then incubated with 5610
5 freshly isolated OT-II CD4
+ T cells at
various DC dilutions. C) SPIO labelled and unlabelled DCs (4 h at 100 mg/mL SPIO) were LPS treated and C57BL/6 DCs were incubated with 5610
5
freshly isolated CBA/Ca CD4
+ T cells at various DC dilutions in a mixed lymphocyte reaction (MLR). In all in vitro experiments, cells were treated with
tritiated thymidine on day three for 16 h to quantify proliferation. Experiments were repeated three times and data points are represented as the
average of triplicate 6 SE.
doi:10.1371/journal.pone.0019662.g002
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However, it was reported that at day 7, there were 50% less
fluorescent DCs present in the LN than at day 2. This could be
due in part to host DCs and macrophages engulfing and trafficking
MPIO to the LN or to the slow clearance of MPIO from the LN
after DC death in the LN [9].
The SUMO positive contrast technique together with imaging
with varying TEs are sensitive techniques that can be used not
only for DC migration but other cell tracking studies using SPIOs.
SUMO allows the viewer to see dark pixels in an image due to
susceptibility more easily and might also be used to provide
quantitative information [19]. Using SPIO labelled DCs it can
show the presence intra-nodal as opposed to the supcapsular sinus.
The creation of T2
* maps from acquisition at different TEs has
the potential to be used for quantification of iron in vivo. Using the
signal intensity at every voxel at different TEs allows a signal decay
curve to be used to produce a map that relates to the iron
concentration. This was shown in phantom experiments and was
also used to confirm compartmentalization of SPIO by DCs
(Figure S2). In the in vivo DC migration study, however, the
creation of a map was difficult because the signal intensity in the
popliteal LN at a TE of 4.6 ms had already decayed. The effect of
the iron resulted in T2
* relaxation times too short for accurate
measurement in the popliteal LN. This is due to too many SPIO
labelled DCs migrating to the LN resulting in strong hypointensity
at short TEs. It is possible to acquire MR images at shorter TEs to
help produce a T2
* map, but it is not possible with the high-
resolution parameters used in this MR acquisition. However, it
would also be possible to titrate the number of SPIO labelled DCs
injected so that quantification of DC migration is possible.
Figure 3. In vivo MR imaging of SPIO DCs. 1610
6 SPIO labelled or
unlabelled DCs were injected s.c. in the right or left heel, respectively.
A) The region encompassing the popliteal LNs was imaged serially over
96 h to observe the increase in size of both popliteal LN and detect
hypointensity in the right popliteal LN. B) The growth of the popliteal
LNs over time after injection of SPIO labelled or unlabelled DCs was
analysed as the percentage growth in volume compared to the volume
of the LN at 4 h post-injection. The percentage increase in LN volume
was not significantly different between SPIO labelled and unlabelled
DCs (P=0.1888). Shown is a representative example of one experiment
expressed as the average of triplicate 6 SE.
doi:10.1371/journal.pone.0019662.g003
Figure 4. SPIO positive contrast in LN. 1610
6 SPIO labelled or
unlabelled DCs were injected s.c. in the right or left heel, respectively.
A) MR image at 48 h post-DC injection. Positive contrast images by
SUMO at 48 h post-DC injection provide direct comparison of SPIO
labelled and unlabelled DCs are compared in B) and C), respectively. D)
Measurement of the susceptibility gradient, Gs, in LNs from SUMO
parameter maps over the longitudinal study indicates that Gs was
significantly higher for SPIO labelled DCs than unlabelled DC (P=0.038).
doi:10.1371/journal.pone.0019662.g004
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demonstrated that SPIO had no drastic effect on in vivo DC
function, including: (i) the growth of popliteal LNs after s.c. DC
injection, (ii) the PI and % original dividing cells in the in vivo
proliferation assay, and (iii) the ability of DCs to protect mice from
tumour challenge in the B16-Ova melanoma lung metastases
model. Previous reports using an ex vivo proliferation assay stated
that SPIO labelling of DCs affects the proliferation of T cells [4,6].
Dekaban et al. showed that the endocytic function was decreased
in SPIO labelled DCs when KLH was used as a whole antigen [6].
In the in vivo proliferation assay described here, the Ova peptide is
used instead of whole Ova protein. This negates the effect of the
DCs having to engulf intact antigen. Therefore, the assay does not
monitor for the processing and presenting capabilities of DCs. In
order to avoid the problem of antigen pulsing, other studies have
shown that transfection of DCs to express tumour specific antigens
improves DC based tumour vaccination [20].
The B16 murine melanoma tumour model was used to compare
the effect of SPIO labelling on DC vaccination capabilities. It
should be noted, however, that both the B16 cells and ex vivo
expanded DCs were cultured in media that contains FBS. Due to
this, it is possible that ‘bystander’ immune responses could be
elicited by the DCs against components of the FBS that are
expressed on B16 tumour cells. This can lead to an anti-tumour
effect and could be the reason for the decrease in lung nodules
when SPIO labelled DCs not pulsed with Ova257-264 were used as
a control for DC vaccination. This effect of FBS culture conditions
leading to anti-tumour immune responses in the B16 model has
been reported in previous studies [21,22]. Eggert et al. reported
that bone marrow derived DCs, either unloaded or tumour-
associated antigen loaded, cultured in FBS could protect against a
challenge with i.v. or s.c. injected B78-D14, a variant of B16 [21].
However, DCs without FBS in the culture media only led to
protection against B78-D14 when they were loaded with the TRP-
2 peptide of amino acids 180–188 [21]. Toldbod et al. reported
similar results of the antitumour effect of FBS cultured DCs upon
B16 challenge that had also been cultured in FBS [22]. In the B16
model described here, the antigen unpulsed DCs resulted in the
presence of a range of tumour nodules when challenged with B16
tumour injection and SPIO labelling procedure did not effect the
ability of Ova257-264 pulsed DCs to completely eliminate Ova257-
264 expressing tumour cells. However, the possibility remains that
uptake of dead SPIO DCs or DC exosomes by lymph node
resident DCs, which then act as antigen presenting cells cannot be
ruled out.
In conclusion we have demonstrated for the first time a direct
comparison of SPIO DCs to their unlabelled counterparts in vivo.
The conditions described here for SPIO labelling of DCs
Figure 5. SPIO DCs induce in vivo T cell proliferation. 3610
6 CFSE labelled OT-II CD4
+ T cells were injected i.v. The next day, 1610
66 SPIO, LPS
treated, OVA323-333 pulsed DCs were injected s.c. heel. Four days later the mesenteric (A) and popliteal (B) LNs were harvested, stained with anti-CD4-
APC and analysed by flow cytometry. (C) Regions of interest highlighted in (A) and (B) are shown as representative histograms and show the
proliferation peaks of CFSE labelled OT-II CD4
+ T cells in the control mesenteric LN (top panel), popliteal LN from mice which received unlabelled DCs
(middle panel) and popliteal LN from mice receiving SPIO DCs (bottom panel). (D) Proliferation index 6 SD after five divisions of CFSE labelled OT-II
CD4
+ T cellsshows specific proliferation andno significant difference proliferation in popliteal LNs from mice which received DCspulsed with OVA323-333
with and without SPIO (P=0.061). These are representative examples of three individual experiments where non-pulsed DCs are run individually and
pulsed DCs are run in triplicate.
doi:10.1371/journal.pone.0019662.g005
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migration and, in combination with MRI quantification tech-
niques, are the basis for future evaluation of DC immunotherapy
in the clinic.
Supporting Information
Figure S1 Prussian blue staining of SPIO labelled DCs.
A) Unlabelled and B) SPIO labelled DCs for 4 h at 37uC and 100
mg/mL of SPIO are fixed and stained with Prussian blue. C)
Lower magnification image of SPIO labelled DCs.
(TIF)
Figure S2 R2,R 2* and R2’ maps of MR Image using a
1.5 T clinical MRI scanner. Transverse relaxation rates were
used to distinguish intracellular versus free SPIO by the equation
R2’=( R 2*-R 2). A)R 2*, B)R 2 and C)R 2’ maps. D) Values of the
maps. Tube numbers 1–7 were free SPIO suspended in gelatin at
2-fold dilutions from 50 mg/mL to 0.78 mg/mL. Tube 8 was
gelatin only. Tube numbers 9–13 were of DCs labelled with 100
mg/mL SPIO for 4 h at 1610
6 cells/mL and decreasing in 2-fold
dilutions. Tube numbers 14-18 were of DCs labelled with 50 mg/
mL SPIO for 4 h at 1610
6 cells/mL and decreasing in 2-fold
dilutions. Tube number 19 is of unlabelled DCs at 1610
6 cells/
mL.
(TIF)
Figure S3 DC Phenotype analysis by flow cytometry.
DCs were treated with 100 mg/mL SPIO for 4 h at 37uC and
stained for the following phenotypic markers: CD11c, CD40,
CD54, CD80, CD86, MHC-I, MHC-II and CCR7, (A)–( H)
respectively. Green line: plus SPIO. Pink line: no SPIO. Solid
purple: respective isotype controls. n = 3.
(TIF)
Figure S4 Effect of increased TE on MR image. DCs
labelled and unlabelled with SPIO were injected in the right and
left legs, respectively. MR images 48 h post-DC injection at TEs of
4.6, 9.2 and 13.8 ms shown in (A), (B), and (C), respectively.
(TIF)
Figure S5 Prussian blue histology. 48 h post-SPIO labelled
DC injection, popliteal LNs were isolated and snap frozen in
OCT. A) Prussian blue staining reveals a strong iron stain in the
subcapsular sinus. B) A zoom image in the center of the image
reveals the presence of iron in the center of the LN. C) Prussian
blue stain of SPIO unlabelled DCs in popliteal LN. D) Single cell
in popliteal LN after SPIO labelled DC injection.
(TIF)
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